Received by email:

File: News Release - Stock Options Granted Final 10.26.17.pdf

890 West Pender Street, Suite 600                                                     69 Longwood Avenue
Vancouver, British Columbia                                                           Hyannis Port, MA,02647 USA
Canada V6C 1J9                                                                        617-571-6006
778-998-5000                                                                          www.imaginmedical.com




CSE Symbol: IME                                                                       NR-2017-IME - 18
OTC Pink Symbol: IMEXF
Frankfurt/Stuttgart Stock Exchange: DPD2



           Imagin Medical Announces Stock Options Granted
Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will
establish a new standard of care for urologists in detecting cancers and visualizing the
surgical field in minimally invasive surgery. The Company's initial focus is bladder cancer.
______________________________________________________________________


Vancouver, B.C. and Boston, MA, October 26, 2017   Imagin Medical (CSE: IME) (OTC
PINK: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the "Company") announced today
that pursuant to the Company's Stock Option Plan, an aggregate of 2,250,000 shares
have been granted to certain directors, officers and consultants as incentive stock options
at an exercise price of $0.18 per share. The options are exercisable for a period of five
years, ending on October 26, 2022.

About Imagin Medical
Imagin Medical is developing imaging solutions for minimally invasive surgical procedures
where endoscopes are used. The Company believes it will radically improve the way
physicians detect cancer and view the surgical field. Imagin's initial target market is
bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the
most costly cancer to treat due to a greater than 50% recurrence rate. The ultrasensitive
imaging technology is based upon improved optical designs and advanced light sensors.
Learn more at www.imaginmedical.com


For further information, contact:
Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: jhutchens@imaginmedical.com

Information set forth in this news release contains forward-looking statements. These statements reflect
management's current estimates, beliefs, intentions and expectations; they are not guarantees of future
performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual
performance may be affected by a number of material factors, many of which are beyond the Company's control.
Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs,
intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no
 assurance the Company's imaging system will work in the manner expected, e xcept as required under applicable
securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking
information. The CSE has neither approved nor disapproved the information contained herein and does not accept
responsibility for the adequacy or accuracy of this news release.




{00858280;1}